Bilirubin has potential predictive and prognostic value for myocardial infarction (MI), but the clinical evidence remains controversial. We performed this meta-analysis to systematically quantify the relationships between circulating bilirubin levels and the incidence of MI and post-MI adverse events. We searched the PubMed, Cochrane Library, Embase, and Web of Science databases for ad-hoc studies, published… Continue reading Physiologically increased total #bilirubin is associated with reduced risk of first #myocardial infarction: A meta-analysis and dose-response analysis
Category: Hepatology
#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis
We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased… Continue reading #Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis
Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics… Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?
The revolution of the antiviral treatment of hepatitis C virus (HCV) infection resulting in higher effectiveness came with the introduction of direct‐acting antivirals with pangenotypic regimens as a final touch. Among them, the combination of glecaprevir (GLE) and pibrentasvir (PIB) provides the opportunity for shortening therapy to 8 weeks in the majority of patients. Because… Continue reading Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?
JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show a 71% (95% CI 0.15-0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age 81 years). A further 48 cases with mild-moderate pneumonia recovered uneventfully. Using organotypic 3D cultures… Continue reading JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to… Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
Associations between #Helicobacter pylori with nonalcoholic fatty #liver disease and other metabolic conditions in Guatemala
Previous studies have suggested an association between Helicobacter pylori (H pylori) and nonalcoholic fatty liver disease (NAFLD). The aim of the current study was to examine the association in Guatemala, a region with elevated prevalences of both H pylori and NAFLD. Associations between H pylori and other metabolic conditions were also examined, as were associations… Continue reading Associations between #Helicobacter pylori with nonalcoholic fatty #liver disease and other metabolic conditions in Guatemala
GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals
Hepatocellular carcinoma (HCC) risk persists after hepatitis C virus (HCV) eradication with direct‐acting antivirals (DAAs), particularly in patients with cirrhosis. Identifying those who are likely to develop HCC is a critical unmet medical need. Our aim is to develop a score that offers individualized patient HCC risk prediction.. ..In the derivation cohort, the median follow‐up… Continue reading GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals
Inadequate #Physical Activity and #Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty #Liver Disease
In general, physical activity (PA) and nonalcoholic fatty liver disease (NAFLD) have an inverse association. However, studies assessing the impact of the widely accepted Physical Activity Guidelines for Americans (PA Guidelines) on NAFLD are lacking. We performed a serial, cross‐sectional analysis among adults by using the 2007‐2016 US National Health and Nutrition Examination Survey. NAFLD… Continue reading Inadequate #Physical Activity and #Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty #Liver Disease
